<DOC>
	<DOCNO>NCT00160459</DOCNO>
	<brief_summary>This study design determine safety effectiveness 3 asoprisnil dos compare placebo , take 12 week woman uterine fibroid .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Asoprisnil Treatment Uterine Fibroids</brief_title>
	<detailed_description>No medical therapy currently available long-term treatment uterine fibroid . The objective study determine safety efficacy asoprisnil 5 mg , 10 mg 25 mg , compare placebo , take daily 12 week woman one uterine fibroid , confirm ultrasound . Upon completion , subject participate site allow enter open-label extension study</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Women 18 49 year age Diagnosis either 1 uterine fibroid History regular menstrual cycle 21 35 day length . Any abnormal lab result studydoctor considers significant History severe reaction current use hormone therapy History osteoporosis bone disease History uterine artery embolization , cryomyolysis , electrical myolysis Subject currently breast feed Hemoglobin &lt; 8 g/dL baseline</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Fibroid Uterus</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>asoprisnil</keyword>
</DOC>